Federal Laboratory Consortium "Labs in Action" video highlights successful collaboration that resulted in the commercialization of Yescarta®, a highly personalized CAR T-cell immunotherapy.
A new video produced by the Federal Labs Consortium (FLC) as part of their Labs in Action series highlights the successful partnership between NCI and Kite Pharma, Inc. that resulted in the commercialization of Yescarta®, a highly personalized CAR T-cell immunotherapy. Yescarta was approved by the FDA on October 18, 2017 for patients with large-B-cell lymphomas whose cancer has progressed after receiving at least two prior treatment regimens.
Axicabtagene was developed by Steven Rosenberg, M.D., Ph.D. (chief, Surgery Branch, Center for Cancer Research) and his colleagues. The technology was licensed to Kite Pharma, Inc. as part of a broader research agreement for further development and commercialization after promising early-phase clinical trials conducted at NCI. Featured in the video to discuss the technology transfer perspective, Drs. Aida Cremesti and Andrew Burke, both senior technology transfer managers in TTC, remark on the technology transfer aspects of this significant partnership. “The technology transfer office has been vital to our ability to move from the laboratory into widespread clinic application,” commented Dr. Rosenberg. To learn more, watch the video.